Acute myeloid leukemia: Clinical Practice Guidelines in Oncology

Margaret R. O'Donnell; Frederick R. Appelbaum; Maria R. Baer; John C. Byrd; Steven E. Coutre; Lloyd E. Damon; Harry P. Erba; Eli Estey; James Foran; Jeffrey Lancet; Lori J. Maness; Peter G. Maslak; Michael Millenson; Joseph O. Moore; Donna Przepiorka; Paul Shami; B. Douglas Smith; Richard M. Stone; Martin S. Tallman

doi:10.6004/jnccn.2006.0004

Acute myeloid leukemia: Clinical Practice Guidelines in Oncology

Margaret R. O'Donnell, Frederick R. Appelbaum, Maria R. Baer, John C. Byrd, Steven E. Coutre, Lloyd E. Damon, Harry P. Erba, Eli Estey, James Foran, Jeffrey Lancet, Lori J. Maness, Peter G. Maslak, Michael Millenson, Joseph O. Moore, Donna Przepiorka, Paul Shami, B. Douglas Smith, Richard M. Stone, Martin S. Tallman

School of Medicine

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Approximately 11,960 people will be diagnosed with acute myeloid leukemia (AML) in 2005, and 9,000 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of tumors of childhood and young adulthood such as Hodgkin's disease, sarcomas, breast and testicular cancers, and lymphomas. Recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for AML patients, particularly older patients, have not substantially changed in the past 3 decades.

Original language	English (US)
Pages (from-to)	16-36
Number of pages	21
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	4
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2006.0004
State	Published - Jan 2006

Keywords

Acute myeloid leukemia
Chemotherapeutic agents
Cytogenetics
Leukemia treatment
NCCN Clinical Practice Guidelines

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2006.0004

Cite this

O'Donnell, M. R., Appelbaum, F. R., Baer, M. R., Byrd, J. C., Coutre, S. E., Damon, L. E., Erba, H. P., Estey, E., Foran, J., Lancet, J., Maness, L. J., Maslak, P. G., Millenson, M., Moore, J. O., Przepiorka, D., Shami, P., Smith, B. D., Stone, R. M., & Tallman, M. S. (2006). Acute myeloid leukemia: Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network, 4(1), 16-36. https://doi.org/10.6004/jnccn.2006.0004

O'Donnell, MR, Appelbaum, FR, Baer, MR, Byrd, JC, Coutre, SE, Damon, LE, Erba, HP, Estey, E, Foran, J, Lancet, J, Maness, LJ, Maslak, PG, Millenson, M, Moore, JO, Przepiorka, D, Shami, P, Smith, BD, Stone, RM & Tallman, MS 2006, 'Acute myeloid leukemia: Clinical Practice Guidelines in Oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 4, no. 1, pp. 16-36. https://doi.org/10.6004/jnccn.2006.0004

@article{c34c34e0d05a447aa02b684b3614baf3,

title = "Acute myeloid leukemia: Clinical Practice Guidelines in Oncology",

abstract = "Approximately 11,960 people will be diagnosed with acute myeloid leukemia (AML) in 2005, and 9,000 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of tumors of childhood and young adulthood such as Hodgkin's disease, sarcomas, breast and testicular cancers, and lymphomas. Recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for AML patients, particularly older patients, have not substantially changed in the past 3 decades.",

keywords = "Acute myeloid leukemia, Chemotherapeutic agents, Cytogenetics, Leukemia treatment, NCCN Clinical Practice Guidelines",

author = "O'Donnell, {Margaret R.} and Appelbaum, {Frederick R.} and Baer, {Maria R.} and Byrd, {John C.} and Coutre, {Steven E.} and Damon, {Lloyd E.} and Erba, {Harry P.} and Eli Estey and James Foran and Jeffrey Lancet and Maness, {Lori J.} and Maslak, {Peter G.} and Michael Millenson and Moore, {Joseph O.} and Donna Przepiorka and Paul Shami and Smith, {B. Douglas} and Stone, {Richard M.} and Tallman, {Martin S.}",

year = "2006",

month = jan,

doi = "10.6004/jnccn.2006.0004",

language = "English (US)",

volume = "4",

pages = "16--36",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "1",

}

TY - JOUR

T1 - Acute myeloid leukemia

T2 - Clinical Practice Guidelines in Oncology

AU - O'Donnell, Margaret R.

AU - Appelbaum, Frederick R.

AU - Baer, Maria R.

AU - Byrd, John C.

AU - Coutre, Steven E.

AU - Damon, Lloyd E.

AU - Erba, Harry P.

AU - Estey, Eli

AU - Foran, James

AU - Lancet, Jeffrey

AU - Maness, Lori J.

AU - Maslak, Peter G.

AU - Millenson, Michael

AU - Moore, Joseph O.

AU - Przepiorka, Donna

AU - Shami, Paul

AU - Smith, B. Douglas

AU - Stone, Richard M.

AU - Tallman, Martin S.

PY - 2006/1

Y1 - 2006/1

N2 - Approximately 11,960 people will be diagnosed with acute myeloid leukemia (AML) in 2005, and 9,000 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of tumors of childhood and young adulthood such as Hodgkin's disease, sarcomas, breast and testicular cancers, and lymphomas. Recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for AML patients, particularly older patients, have not substantially changed in the past 3 decades.

AB - Approximately 11,960 people will be diagnosed with acute myeloid leukemia (AML) in 2005, and 9,000 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of tumors of childhood and young adulthood such as Hodgkin's disease, sarcomas, breast and testicular cancers, and lymphomas. Recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for AML patients, particularly older patients, have not substantially changed in the past 3 decades.

KW - Acute myeloid leukemia

KW - Chemotherapeutic agents

KW - Cytogenetics

KW - Leukemia treatment

KW - NCCN Clinical Practice Guidelines

UR - http://www.scopus.com/inward/record.url?scp=33645053537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645053537&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2006.0004

DO - 10.6004/jnccn.2006.0004

M3 - Review article

C2 - 16403402

AN - SCOPUS:33645053537

SN - 1540-1405

VL - 4

SP - 16

EP - 36

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 1

ER -

Acute myeloid leukemia: Clinical Practice Guidelines in Oncology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this